DEFINITIVE CONTRACT
Active75F40126C00055
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$752.3K
obligated · signed 2 months ago
BAA FY26C1FP7 MD ANDERSON ONCOLOGY CENTER FOR EXCELLENCE (OCE), EVALUATING BAYESIAN EFFECTIVE SAMPLE SIZE AND DECISION CRITERIA FOR PEDIATRIC AND RARE DISEASE TRIALS
Performance timeline
Start
Sep 30, 2026
End
Sep 29, 2028
with all options
Loading status
Estimated start: Sep 29, 2027
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER
Contract 75F40126C00055
UEI
S3GMKS8ELA16
Parent Company
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER
Capabilities & Certifications
Headquarters Location
Congressional District: 09
Current Obligation
$752,304
Base + Exercised Options
$752,304
Total Ceiling Value
$752,304
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
Place of Performance
Congressional District: 09
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.